I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.
August 23, 2017
Yesterday, the IBB +1.92%, the XBI +2.39%, The XLV +1.21% and the IWM +1.08% were up as the VIX was down -13.95% and sector volume was below even normal
… With a “happy” high, a low usually follows
Preview RMi's morning call. To get the pre-open briefing, plus daily access to the happenings and realities of “our” universe - SUBSCRIBE!
Pre-open indications: 3 BUYs and 2 SELLs
June 1, 2017
Calling out the recent 10-Q page 17’s paragraph re a 24 page legal filing - this is what BSTG did NOT want investors to know or read!
August 22, 2017
A response to speculation and oversold conditions
While sentiment is overlooked and volume is still very low
As I had stated this a.m., “buy the oversold at a bottom and bid’em up to exit as many become overbought.”
Pre-open indications: 3 hits and 1 miss
Out and about: Biostage (BSTG) makes yet another low of -5.27% or -0.0148 to $0.26 after being down -10.44% to $0.25, a far cry from Q1/17’s start at $0.87, Q1/16’s $2.60, Q1/15’s $4.43 … a “walking dead” company who can’t even get an IND filed as their proof of concept was found “unable to be filed” having burned through $30 M and whose current +$3 M funding is all about salary continuation with a new development “tunnel ”! And I was initially their biggest supporter …
It’s called premium content for a reason … I define insight from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!
Others don’t even come close!
I answer one question, in which company should investors commit and keep their money.
June 27, 2017
On track for top-line 1 year powered data and potential BLA filing in Q3/18 BLA to the FDA shortly thereafter and, if approved, launching NeoCart in the second half of 2019
June 26, 2017
BLUE closed down -$4.20 to $1.06.90 after Monday's -$0.90 or -0.80% to $111.10
June 20, 2017
SGMO closes UP +$0.25 to $8.20 and promptly dives -$0.70 or -8.54% to $7.50 SGMO prices 10 M shares at $7.25
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
8 hours 8 min ago
RegMed Investors’ (RMi) pre-open indications, watch your corners
© 2017 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
